SCHEMBL7797656

SCHEMBL7797656

CCOC(=O)C[C@H](Cc1ccc(O)cc1)c1cccnc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGB3 P05106 1/20 0.44
ITGB1 P05556 1/20 0.44
ITGAV P06756 1/20 0.44
ITGB6 P18564 1/20 0.44
OPRM1 P35372 1/20 0.44
F2 P00734 3/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
ESR1 P03372 4/20 0.40
ESR2 Q92731 4/20 0.40
F10 P00742 2/20 0.40
PRSS1 P07477 1/20 0.40
CYP3A4 P08684 1/20 0.40
CDC7 O00311 1/20 0.39
DBF4 Q9UBU7 1/20 0.39
CYP17A1 P05093 1/20 0.39
GAA P10253 1/20 0.39
MAPK1 P28482 1/20 0.39
PDE4D Q08499 1/20 0.38
TBXAS1 P24557 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6492125 1.00 ITGB3 (0.44) ITGB3ITGB1ITGAVITGB6OPRM1
SCHEMBL7808018 0.88 ITGB3 (0.47) ITGB3ITGB1ITGAVITGB6MEN1
SCHEMBL27509317 0.88 ITGB3 (0.47) ITGB3ITGB1ITGAVITGB6MEN1
SCHEMBL8329187 0.85 F2 (0.55) OPRM1F2ESR1ESR2F10
SCHEMBL27224522 0.83 MEN1 (0.44) F2MEN1KMT2ACYP3A4CDC7
SCHEMBL6491322 0.82 ITGB3 (0.56) ITGB3ITGB1ITGAVITGB6OPRM1
SCHEMBL6493601 0.82 ITGB3 (0.56) ITGB3ITGB1ITGAVITGB6OPRM1
SCHEMBL27396676 0.81 ITGB3 (0.45) ITGB3ITGB1ITGAVITGB6F2
SCHEMBL27224515 0.81 F2 (0.46) F2MEN1KMT2AF10PRSS1
SCHEMBL6533433 0.79 F10 (0.47) OPRM1F2ESR1ESR2F10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6881736-B1 Vitronectin receptor antagonists SMITHKLINE BEECHAM CORPORATION (US) 2005-04-19 US disclosed
US-6881736-B1 Vitronectin receptor antagonists SMITHKLINE BEECHAM CORPORATION (US) 2005-04-19 US disclosed